Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 3, 2002, Pages 670-676

  Poggi, Matthew M ^a   Kroog, Glenn S ^a   Russo, Angelo ^a   Muir, Christine ^a   Cook, John ^a   Smith, Judith ^a   Mitchell, James B ^a   Herscher, Laurie L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Gemcitabine; Pancreas; Radiation; Sensitizer

Indexed keywords

CHEMOTHERAPY; DRUG DOSAGE; RADIOTHERAPY; TOXICITY; TUMORS;

DOSE -LIMITING TOXICITIES;

ONCOLOGY;

GEMCITABINE; RADIOSENSITIZING AGENT;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG INFUSION; FATIGUE; FEMALE; HUMAN; HYPOTENSION; INFECTION; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PANCREAS CARCINOMA; PANCREAS RESECTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOSENSITIZATION; THROMBOCYTOPENIA; THROMBOSIS; TUMOR VOLUME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS;

EID: 0036837319     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02980-2     Document Type: Article

References (20)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., et al. Cancer statistics, 2001. CA Cancer J Clin. 51:2001;15-36.
2. National Cancer Institute . Annual cancer statistics review 1973-1988. NIH Publication No. 91-2789. 1991;DHHS, Bethesda.
3. Gastrointestinal Tumor Study Group, Moertel C.G., Frytak S., Hahn R.G., et al. Therapy of locally unresectable pancreatic carcinoma A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil . Cancer. 48:1981;1705-1710.
4. Plunkett W., Huang P., Xu Y.Z., et al. Gemcitabine Metabolism, mechanism of actions, and self-potentiation . Semin Oncol. 22:1995;3-10.
5. Hertel L.W., Boder G.B., Kroin J.S., et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res. 15:1990;4417-4422.
6. Burris H.A., Moore M.J., Anderson J., et al. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer A randomized trial . J Clin Oncol. 15:1997;2403-2413.
7. Lawrence T.S., Eisbruch A., Shewach D.S. Gemcitabine-mediated radiosensitization. Semin Oncol. 24:(Suppl. 7):1997;24-28.
8. Milas L., Fujii T., Hunter N., et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. 59:1999;107-114.
9. Blackstock A.W., Bernard S.A., Richards F., et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol. 12:1999;2208-2212.
10. Pipas M.J., Mitchell S.E., Barth R.J., et al. Phase I study of twice-weekly gemcitabine and concomitant external beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 50:2001;1317-1322.
11. Hietaniemi K., Karkkainen P., Kiviluoto T., et al. Phase I-II trial of twice-weekly gemcitabine (GEM) and concomitant irradiation in patients (Pts) with locally advanced pancreatic cancer. [Abstract] Proc Am Soc Clin Oncol. 20:2001;. (abstr. 2318).
12. Kornek G.V., Pötter R., Selzer E., et al. Combined radiotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusion gemcitabine. Int J Radiat Oncol Biol Phys. 49:2001;665-671.
13. Talamonti M.S., Catalano P.J., Vaughn D.J., et al. Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer A regimen with unexpected early toxicity . J Clin Oncol. 18:2000;3384-3389.
14. McGinn C.J., Zalupski M.M., Shureiqi I., et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 19:2001;4202-4208.
15. Wong S., Oza A., Brierley J., et al. Phase I study of gemcitabine (G) and escalating dose radiation therapy (RT) in patients with pancreatic carcinoma. [Abstract] Proc Am Soc Clin Oncol. 19:2000;. (abstr. 1041).
16. Wolff R.A., Evans D.B., Gravel D.M., et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res. 7:2001;2246-2253.
17. Blackstock A.W., Tempero M.A., Niedwiecki D., et al. Cancer and Leukemia Group B (CALGB) 89805 Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas . [Abstract] Proc Am Soc Clin Oncol. 20:2001;. (abstr. 627).
18. Schiller J.H., Harrington D., Sandler A., et al. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). [Abstract] ASCO. 19:2000;. (abstr. 2).
19. Sunwoo J.B., Herscher L.L., Kroog G.S., et al. Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. J Clin Oncol. 19:2001;800-811.
20. Touroutoglou N., Gravel D., Raber M.N., et al. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol. 9:1998;1003-1008.